Get the Stockscreener App
84.06
0.73%
0.61
After Hours:
84.04
-0.02
-0.02%
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $84.06, with a volume of 767.57K.
It is up +0.73% in the last 24 hours and down -3.76% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$83.45
Open:
$83.93
24h Volume:
767.57K
Relative Volume:
0.97
Market Cap:
$41.58B
Revenue:
$9.76B
Net Income/Loss:
$1.16B
P/E Ratio:
35.92
EPS:
2.34
Net Cash Flow:
$665.00M
1W Performance:
-1.86%
1M Performance:
-3.76%
6M Performance:
-4.62%
1Y Performance:
+12.30%
1-Day Range:
$83.69
$84.35
1-Week Range:
$82.76
$85.50
52-Week Range:
$74.30
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
84.06 | 41.58B | 9.76B | 1.16B | 665.00M | 2.34 |
|
ISRG
Intuitive Surgical Inc
|
535.29 | 190.66B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
228.46 | 66.26B | 20.18B | 1.71B | 3.07B | 5.94 |
|
RMD
Resmed Inc
|
231.67 | 34.01B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
335.56 | 24.30B | 2.88B | 499.60M | 321.60M | 6.74 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Seeing Brilliance in APAC: Alcon’s Vision Care Innovations and Eye Health Mission - BSA bureau
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Alcon Laboratories issues recall for Systane eye drops due to fungal contamination - Top Class Actions
News Release – DOH Issues Recall Alert For Alcon Laboratories Systane Brand Lubricant Eye Drops Due to Fungal - EIN News
DOH issues recall alert for Alcon Laboratories Systane Brand Lubricant Eye Drops - Maui Now
Alcon Labs recalling eye drops - Valley News
Alcon Laboratories Recalls Systane Eye Drops Nationwide Over Fungal Contamination Risk - Black Enterprise
Alcon's (VTX:ALC) investors will be pleased with their respectable 41% return over the last five years - Simply Wall St
Alcon Laboratories Recalls Systane Eye Drops Over Fungal Risk - Franklin County Free Press
Ocular Prosthesis Market Trends, Challenges and Opportunities to 2030: A Projected $2.3 Billion Landscape - GlobeNewswire Inc.
Refractive Surgery Market Growth in Future Scope 2024-2031 | - openPR
Alcon Labs Recalls Systane Lubricant Eye Drops Over Fungal Contamination - Nasdaq
Retinal Laser Photocoagulation Market Top PlayersAlcon, A.R.C Laser, Ellex Medical, Carl Zeiss, Quantel Medical. - openPR
Here's Why Alcon (ALC) is a Strong Growth Stock - MSN
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - GlobeNewswire
Alcon Laboratories Issues Voluntary Nationwide Recall of One (1) Lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101), Due to Fungal Contamination - US Recall News
Alcon a top pick for 2025 at Needham on upcoming product launches - MSN
Alcon Top Pick for 2025 at Needham, added to Conviction List - MSN
Alcon stock named top pick for 2025 by Needham, positive on margin and earnings growth - Investing.com Australia
RSI Alert: Alcon (ALC) Now Oversold - Nasdaq
Reasons to Retain Alcon Stock in Your Portfolio for Now - MSN
Does Alcon (VTX:ALC) Have A Healthy Balance Sheet? - Simply Wall St
Alcon Loses Bid To Patent Improved Eye Drug At EPO - Law360
Alcon to lay off dozens of food service workers at Fort Worth campus on Christmas Eve - Yahoo! Voices
Why Alcon (ALC) is a Top Growth Stock for the Long-Term - Yahoo Finance
Alcon Inc. (ALC): A Bull Case Theory - MSN
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart
Photobiomodulation Market Overall Study Report 2024-2031 | - openPR
Dry Eye Disease Market Outlook to 2034: Insights into Epidemiology, Pipeline Developments, and Recent Regulatory Approvals by DelveInsight | Featuring Major Players Like Alcon, Allysta Pharmaceuticals - The Globe and Mail
Ocular Trauma Devices Market Is Booming Worldwide with Alcon, Zeiss, Santen - openPR
India Contact Lenses Market Forecasts and Company Analysis Report 2023-2024 & 2032 Featuring Bausch & Lomb, Alcon Laboratories, J&J, Cooper Vision, Carl Zeiss, Hoya Medical, GKB Ophthalmic and Omni - Yahoo Finance
State Rep. Alcon steps down, cites health concerns - New Mexico Political Report
Jesse Alcon Obituary (2024)Price, UTMitchell Funeral Home, Inc.Price - Legacy.com
Alcon, '3D eye model implementation'Personal vision correction'Personal Eyes' launched in Korea - SportsChosun
What Analyst Projections for Key Metrics Reveal About Alcon (ALC) Q3 Earnings - MSN
Alcon cuts 2024 forecasts, as slow US hits surgical unit - MSN
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours - MSN
Impressive Earnings May Not Tell The Whole Story For Alcon (VTX:ALC) - Yahoo Finance
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Most Venture Investors Want Their Startups to Go Public. Not This One. - The Wall Street Journal
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Results: Alcon Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):